A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin
Latest Information Update: 02 Feb 2026
At a glance
- Drugs Empagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMPAGO
- Sponsors Chong Kun Dang
Most Recent Events
- 02 Feb 2026 New trial record